Interferon-alpha in oncology patients: fewer psychiatric side effects than anticipated.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Psychosomatics

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1176/appi.psy.49.1.56PMID 18212177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial.

  2008cited by this paper
• Irritability Rather Than Depression During Interferon Treatment Is Linked to Increased Tryptophan Catabolism

  2005cited by this paper
• Psychiatric side effects of pegylated interferon alfa-2b as compared to conventional interferon alfa-2b in patients with chronic hepatitis C.

  2005cited by this paper
• Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment.

  2005cited by this paper
• Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-α treatment

  2005cited by this paper
• Cytokines and psychopathology: lessons from interferon-alpha.

  2004cited by this paper
• Early increase in vegetative symptoms predicts IFN-α-induced cognitive-depressive changes

  2004cited by this paper
• Cytokine-induced sickness behavior.

  2003cited by this paper
• Incidence and clinical course of major depression in patients with chronic hepatitis type C undergoing interferon-alpha therapy: a prospective study.

  2003cited by this paper
• SCL-90. Handleiding bij een multidimensionele psychopathologie-indicator

  2003cited by this paper
• Neuropsychiatric side effects of interferon‐alfa therapy

  2003cited by this paper
• The validity of the Hospital Anxiety and Depression Scale. An updated literature review.

  2002cited by this paper
• A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C

  2002cited by this paper
• Paroxetine for the prevention of depression induced by high-dose interferon alfa.

  2001cited by this paper
• Timing and Specificity of the Cognitive Changes Induced by Interleukin-2 and Interferon-&agr; Treatments in Cancer Patients

  2001cited by this paper
• Neuropsychiatric symptoms associated with hepatitis C and interferon alpha: A review.

  2000cited by this paper
• Illness, Cytokines, and Depression

  2000cited by this paper
• The malaise theory of depression: major depressive disorder is sickness behavior and antidepressants are analgesic.

  2000cited by this paper
• The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

  1998cited by this paper
• Behavioral and psychological effects of immune activation: implications for 'depression due to a general medical condition'

  1997cited by this paper
• Evidence for an immune response in major depression: a review and hypothesis.

  1995cited by this paper
• The prevalence of depression in elderly medical inpatients.

  1995cited by this paper
• Clinical Toxicity of the Interferons

  1994cited by this paper
• Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation

  1988cited by this paper
• Psychiatric complications of long-term interferon alfa therapy.

  1987cited by this paper
• The brief scale for anxiety: a subdivision of the comprehensive psychopathological rating scale.

  1984cited by this paper
• Karnofsky performance status revisited: reliability, validity, and guidelines.

  1984cited by this paper
• The Hospital Anxiety and Depression Scale

  1983cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Confirmation of the dimensional structure of the scl‐90: A study in construct validation

  1977cited by this paper
• SCL-90: an outpatient psychiatric rating scale--preliminary report.

  1973cited by this paper
• The clinical evaluation of chemotherapeutic agents in cancer

  1949cited by this paper

• Psychosocial Aspects of Living Long Term with Advanced Cancer and Ongoing Systemic Treatment: A Scoping Review

  2022influential citation
• Health-related Quality of Life, Fatigue, and Depression Under Low-Dose IFN-&agr; Therapy in Melanoma Patients

  2014cites this paper
• Predictors of Psychopathological Outcome During Peg-Interferon and Ribavirin Therapy in Patients with Chronic HCV-Correlated Hepatitis

  2013cites this paper
• Self‐efficacy for coping with cancer in melanoma patients: its association with physical fatigue and depression

  2013cites this paper
• Psychological Aspects of Hematological Neoplasms

  2013cites this paper
• Interferon-α as an appropriate model of substance-induced depression.

  2011cites this paper
• Interferon-Induced Obsessive-Compulsive Symptoms in Malignant Melanoma

  2011cites this paper
• Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.

  2009cites this paper
• Reply to P. Mohr et al

  2009cites this paper
• Quality of life in patients receiving high-dose interferon alfa-2b after resected high-risk melanoma.

  2009cites this paper
• Central and peripheral nervous system toxicity of common chemotherapeutic agents

  2009cites this paper
• Neurotoxic and neuroprotective metabolites of kynurenine in patients with renal cell carcinoma treated with interferon‐α: Course and relationship with psychiatric status

  2008cites this paper
• Nitric oxide production and monoamine oxidase activity in cancer patients during interferon-α therapy

  2008influential citation
• Plasma Activity of Prolyl Endopeptidase in Relation to Psychopathology During Immunotherapy with IFN-α in Patients with Renal Cell Carcinoma

  2008cites this paper
• Current awareness: Pharmacoepidemiology and drug safety

  2008cites this paper
• Interferon-α Influences Tryptophan Metabolism without Inducing Psychiatric Side Effects

  2007cites this paper